Show simple item record

dc.contributor.authorTreish, Imad
dc.contributor.authorAl Rabayah, Abeer
dc.contributor.authorJaddoua, Saad
dc.contributor.authorTuffaha, Haitham
dc.date.accessioned2021-11-16T04:43:57Z
dc.date.available2021-11-16T04:43:57Z
dc.date.issued2021
dc.identifier.issn2509-4262
dc.identifier.doi10.1007/s41669-021-00293-4
dc.identifier.urihttp://hdl.handle.net/10072/410138
dc.description.abstractRising prices of novel cancer medications are increasing the economic burden from cancer in Jordan, risking the ability of cancer patients to access lifesaving and life-extending treatments. Furthermore, in the absence of a national health technology assessment (HTA) framework, medication prices in Jordan are set based on manufacturers’ pricing considerations and not a value proposition. In response to these challenges, King Hussein Cancer Center (KHCC), the de facto national cancer institute, developed a first-in-country, cancer-specific, cost-effectiveness threshold (CET) to aid institutional decision makers in approving only cost-effective medications. Over the past 10 years, cost-effectiveness analyses based on this CET have led to the introduction of > 70% of requested novel cancer medications after manufacturers agreed to lower prices, beyond registration prices, to meet the CET. Future work is warranted to empirically derive a CET for Jordan to better guide reimbursement decisions.
dc.description.peerreviewedYes
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofjournalPharmacoEconomics - Open
dc.subject.fieldofresearchHealth economics
dc.subject.fieldofresearchPublic health
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode380108
dc.subject.fieldofresearchcode4206
dc.subject.fieldofresearchcode3211
dc.titleImpact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationTreish, I; Al Rabayah, A; Jaddoua, S; Tuffaha, H, Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan, PharmacoEconomics - Open
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2021-11-16T03:26:58Z
dc.description.versionVersion of Record (VoR)
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.
gro.rights.copyright© The Author(s) 2021. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
gro.hasfulltextFull Text
gro.griffith.authorTuffaha, Haitham W.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record